From Wikipedia, the free encyclopedia
Jump to: navigation, search
Phosphodiesterase 4B, cAMP-specific
Protein PDE4B PDB 1f0j.png
PDB rendering based on 1f0j.
Available structures
PDB Ortholog search: PDBe, RCSB
External IDs OMIM600127 MGI99557 HomoloGene1953 IUPHAR: 1301 ChEMBL: 275 GeneCards: PDE4B Gene
EC number
RNA expression pattern
PBB GE PDE4B 211302 s at tn.png
PBB GE PDE4B 203708 at tn.png
PBB GE PDE4B gnf1h03574 at tn.png
More reference expression data
Species Human Mouse
Entrez 5142 18578
Ensembl ENSG00000184588 ENSMUSG00000028525
UniProt Q07343 B1AWC8
RefSeq (mRNA) NM_001037339 NM_001177980
RefSeq (protein) NP_001032416 NP_001171451
Location (UCSC) Chr 1:
66.26 – 66.84 Mb
Chr 4:
102.09 – 102.61 Mb
PubMed search [1] [2]

cAMP-specific 3',5'-cyclic phosphodiesterase 4B is an enzyme that in humans is encoded by the PDE4B gene.[1]

This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. Cyclic nucleotides are important second messengers that regulate and mediate a number of cellular responses to extracellular signals, such as hormones, light, and neurotransmitters. The cyclic nucleotide phosphodiesterases (PDEs) regulate the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. This gene encodes a protein that specifically hydrolyzes cAMP. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.[1][2]

Clinical relevance[edit]

Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder.[1] PDE4B is believed to be the PDE4 subtype involved in the antipsychotic effects of PDE4 inhibitors such as rolipram.[3] PDE4B is involved in dopamine-associated and stress-related behaviours.[4]


AN2728, a boron-containing drug candidate that as of 2015 was under development by Anacor Pharmaceuticals for the topical treatment of psoriasis and atopic dermatitis (atopic eczema).[5][6][7] mainly acting on PDE4B.[7]


  1. ^ a b c "Entrez Gene: PDE4B phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)". 
  2. ^ Swerdlow, Neal R. (2010-08-19). Behavioral Neurobiology of Schizophrenia and Its Treatment (in English). Springer Science & Business Media. ISBN 9783642137174. 
  3. ^ Porteous DJ, Millar JK, Brandon NJ, Sawa A (Dec 2011). "DISC1 at 10: connecting psychiatric genetics and neuroscience". Trends in Molecular Medicine 17 (12): 699–706. doi:10.1016/j.molmed.2011.09.002. PMC 3253483. PMID 22015021. 
  4. ^ Francis, SH; Conti, M; Houslay, MD, ed. (2011). Phosphodiesterases as Drug Targets (PDF). Handbook of Experimental Pharmacology 204. Springer Berlin Heidelberg. doi:10.1007/978-3-642-17969-3. ISBN 978-3-642-17968-6. 
  5. ^ Anacor AN2728 at Anacor website Page accessed May 15, 2015
  6. ^ Nazarian R, Weinberg JM (Nov 2009). "AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis". Current Opinion in Investigational Drugs 10 (11): 1236–42. PMID 19876791. 
  7. ^ a b Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014 May 16;20(5):22608. PMID 24852768

Further reading[edit]